CRYOPORT, INC. Treasury Stock Acquired, Average Cost Per Share
CRYOPORT, INC. (CYRX) reported Treasury Stock Acquired, Average Cost Per Share of $7.73 per share for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2025-11-06
- CRYOPORT, INC. treasury stock acquired, average cost per share for the quarter ending 2025-09-30 was $7.73.
- CRYOPORT, INC. treasury stock acquired, average cost per share for the quarter ending 2023-03-31 was $23.63, a 13.25% decline year-over-year.
- CRYOPORT, INC. treasury stock acquired, average cost per share for the quarter ending 2022-03-31 was $27.24.
- CRYOPORT, INC. treasury stock acquired, average cost per share for fiscal 2022 was $23.63.
| Period end | Treasury Stock Acquired, Average Cost Per Share 1 month | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 6 month | Treasury Stock Acquired, Average Cost Per Share 9 month | Treasury Stock Acquired, Average Cost Per Share 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $7.73 10-Q · filed 2025-11-06 | $7.18 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.76 10-Q · filed 2025-08-12 | ||||
| 2023-03-31 | $23.63 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $23.63 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | $24.84 10-Q · filed 2022-11-04 | ||||
| 2022-06-30 | $24.84 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $27.24 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |